Senti Biosciences Holdings, Inc.

https://www.sentibio.com

Senti Biosciences Holdings, Inc., operating as Senti Bio, is a clinical-stage biotechnology company headquartered in South San Francisco, California. Its mission is to develop a new generation of smarter medicines designed to outmaneuver complex diseases through novel and unprecedented approaches. [3, 4, 5, 10, 14, 17, 18, 25, 26, 32]

The company's core business revolves around its proprietary Gene Circuit platform, which engineers synthetic biology into next-generation cell and gene therapies. These Gene Circuits are created from novel DNA sequences to reprogram cells with biological logic, enabling them to sense inputs, compute decisions, and respond to their cellular environments. Senti Bio primarily applies this technology to develop off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapies for challenging liquid and solid tumor oncology indications. Its lead product candidate, SENTI-202, is a logic-gated CAR-NK cell therapy currently in a Phase 1 clinical trial for relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). SENTI-202 has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for treating relapsed or refractory hematologic malignancies, with a focus on AML. [3, 5, 10, 12, 14, 17, 28, 29, 33, 34, 36]

In recent corporate developments, Senti Biosciences completed a holding company reorganization on April 24, 2026, with Senti Biosciences Holdings, Inc. becoming the successor issuer, and its common stock continuing to trade on the Nasdaq Capital Market under the ticker symbol SNTI. [2, 23] The company also recently secured up to $40 million in senior secured convertible notes financing with an affiliate of Celadon Partners. [19, 23] Preliminary data from the SENTI-202 Phase 1 trial in relapsed/refractory AML has shown a 50% overall response rate and a 39% complete remission rate. [2] The leadership team includes Co-Founder and CEO Dr. Tim Lu, Chief Financial Officer Jay Cross, and President, Head of Research & Development and Chief Medical Officer Dr. Kanya Rajangam. [3, 5, 11, 12, 22]

Latest updates

Senti Biosciences to Detail Logic-Gated Cell Therapy Data at AACR

Event summary

  • Senti Biosciences CEO Timothy Lu will present at the AACR Annual Meeting on April 17, 2026.
  • The presentation will focus on Logic-Gated SENTI-202 cell therapy and its potential in oncology.
  • SENTI-202 is being evaluated in a clinical trial for relapsed/refractory acute myeloid leukemia.
  • Senti Biosciences’ Gene Circuit platform aims to selectively kill cancer cells while sparing healthy cells.

The big picture

Senti Biosciences is attempting to differentiate itself in the crowded cell therapy space with its Logic-Gated approach, which aims to improve precision and efficacy. The AACR presentation provides a key opportunity to validate this strategy and demonstrate clinical progress. The company's success hinges on translating pre-clinical promise into tangible clinical outcomes and establishing a competitive advantage against established therapies.

What we're watching

Clinical Efficacy
The presentation’s discussion of SENTI-202 trial results will be crucial; positive data could significantly boost investor confidence, while negative findings may raise concerns about the platform's viability.
Competitive Landscape
The success of Senti’s Logic-Gated approach will depend on its ability to outperform existing therapies like T cell engagers and antibody-drug conjugates, and the presentation may offer insights into this comparison.
Platform Breadth
While initially focused on oncology, Senti’s pre-clinical work suggests broader applications; the company’s ability to expand Gene Circuit usage beyond cancer will be a key determinant of long-term value.

Senti Biosciences Publishes Data on Logic-Gated CAR Circuits, Bolstering Cell Therapy Approach

Event summary

  • Senti Biosciences published peer-reviewed research in *Cell Systems* detailing its framework for engineering NOT-gated chimeric antigen receptor (CAR) circuits.
  • The study analyzed over 60 CAR circuit designs, identifying LIR1-based receptors as potent regulators of immune cell activity.
  • Findings demonstrate improved tumor cell elimination and reduced cellular exhaustion in T cells and selective elimination of tumor cells in NK cells in vivo.
  • The research supports Senti’s Gene Circuit platform and has led to a patent application.

The big picture

Senti Biosciences’ research underscores the growing trend towards precision cell therapies, moving beyond traditional CAR-T approaches to incorporate more sophisticated logic-based control mechanisms. The ability to engineer immune cells with enhanced specificity and reduced toxicity is crucial for expanding the therapeutic window and addressing the limitations of current cell therapies, which often suffer from off-target effects and patient exhaustion. This publication strengthens Senti’s position in a rapidly evolving market, but the clinical translation of these findings will be key to realizing the platform’s full potential.

What we're watching

Clinical Translation
The success of NOT-gated CAR circuits in preclinical models will need to be replicated in human trials to validate the approach and demonstrate clinical benefit beyond SENTI-202.
Patent Landscape
The strength and breadth of the patent application covering the technology will be critical in protecting Senti’s intellectual property and maintaining a competitive advantage in the crowded cell therapy space.
Platform Adoption
The portability of logic-gated CAR circuits across T and NK cells suggests broader applicability, but the pace at which Senti can expand its Gene Circuit platform to other disease areas remains to be seen.

Senti Bio Data Boosts AML Program, Burns Cash Reserves

Event summary

  • Senti Bio reported $16.4 million in cash and cash equivalents as of December 31, 2025, a significant decrease from $48.3 million in the prior year.
  • Preliminary clinical data from the Phase 1 trial of SENTI-202 in relapsed/refractory AML showed encouraging response rates and a favorable safety profile.
  • The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202 for the treatment of relapsed/refractory AML.
  • Research and development expenses totaled $37.6 million for the full year 2025, while general and administrative expenses were $26.2 million.
  • The company recorded a net loss of $61.4 million for the full year 2025, including $5.1 million in non-recurring asset impairment.

The big picture

Senti Bio's progress on SENTI-202, coupled with the RMAT designation, validates its Gene Circuit platform approach to cell and gene therapy. However, the significant cash depletion underscores the capital-intensive nature of the business and highlights the need for strategic partnerships or additional funding rounds to sustain its pipeline. The company's ability to translate early clinical success into a commercially viable product will be a key factor in its long-term success within a competitive cell and gene therapy landscape.

What we're watching

Financial Runway
The substantial cash burn rate raises questions about Senti Bio’s ability to fund ongoing clinical trials and platform development without additional financing, particularly given the current macroeconomic environment.
Clinical Efficacy
While initial data for SENTI-202 is encouraging, the durability of response and the potential for broader applicability beyond relapsed/refractory AML will be critical determinants of long-term commercial viability.
Platform Expansion
The company’s stated intention to expand the Gene Circuit platform beyond oncology will require significant investment and faces inherent technical and regulatory hurdles.

Senti Biosciences Presents Early AML Trial Data, Highlights Gene Circuit Platform

Event summary

  • Senti Biosciences will present clinical and translational data from its Phase I trial (SENTI-202-101) at the Innate Killer Conference on March 24–25, 2026.
  • SENTI-202 is a logic-gated CAR NK cell therapy targeting CD33 and/or FLT3 in relapsed/refractory acute myeloid leukemia (AML).
  • The trial aims to evaluate the safety and preliminary anti-leukemic activity of SENTI-202.
  • Presentations will include data on the therapy’s logic-gated mechanism of action and correlative analyses.

The big picture

Senti Biosciences is attempting to address a significant unmet need in AML treatment with an off-the-shelf CAR NK cell therapy, a strategy that aims to overcome limitations of traditional CAR-T therapies. The company’s Gene Circuit platform represents a novel approach to cell engineering, but the clinical success of SENTI-202 will be critical to validating this technology and attracting further investment in the competitive cell therapy landscape. The focus on biomarker discovery also signals an attempt to broaden the applicability of the platform beyond oncology.

What we're watching

Clinical Efficacy
The initial clinical data presented will be crucial in assessing the viability of Senti’s logic-gated approach to CAR NK cell therapy, particularly given the challenging patient population of relapsed/refractory AML.
Mechanism Validation
Correlational data supporting the unique logic-gated mechanism of action will be essential to differentiate Senti’s platform from competitors and validate the underlying scientific rationale.
Platform Breadth
The workshop on biomarker discovery suggests Senti is seeking to expand the application of its Gene Circuit platform beyond NK and T cells; the success of this effort will determine the long-term value proposition.

Senti Biosciences to Detail Gene Circuit Platform at TD Cowen Conference

Event summary

  • Senti Biosciences CEO Timothy Lu will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026.
  • The presentation will focus on the company's Gene Circuit technology, pipeline progress, and strategic priorities.
  • The webcast will be available from 3:10 – 3:40 PM ET.
  • Senti Biosciences is developing cell and gene therapies targeting liquid and solid tumor indications.

The big picture

Senti Biosciences' Gene Circuit platform represents a novel approach to cell and gene therapy, a sector attracting significant investment and facing increasing regulatory scrutiny. The company's focus on partnerships signals a strategy to mitigate risk and accelerate development, but also highlights potential limitations in internal capabilities. The conference presentation offers a crucial opportunity to assess the viability of their technology and the clarity of their strategic direction.

What we're watching

Partnership Potential
The emphasis on partnership opportunities suggests Senti may lack the internal resources or expertise to fully develop its pipeline, and the conference presentation will likely reveal the specific areas where external collaboration is sought.
Clinical Validation
Preclinical data has been promising, but the market will scrutinize any updates on clinical trial progress and initial data, as this will be a key driver of investor confidence.
Technology Risk
The Gene Circuit platform, while innovative, carries inherent technological risk; the presentation should clarify how Senti is addressing potential challenges related to circuit stability, specificity, and delivery.

Senti Bio Showcases Logic-Gated Cell Therapy Approach at Cell & Gene Live

Event summary

  • Senti Biosciences participated in the Cell & Gene Live virtual event on February 19, 2026.
  • The event focused on technologies advancing cell therapy development, with Senti Bio highlighting its Gene Circuit platform.
  • SENTI-202, a Logic Gated CAR-NK cell therapy targeting AML and MDS, was specifically mentioned.
  • SENTI-202 has received Orphan Drug Designation (ODD) and Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.

The big picture

Senti Bio's participation in Cell & Gene Live underscores the increasing focus on precision and control within the rapidly evolving cell therapy space. The company's Logic-Gated approach, exemplified by SENTI-202, represents a potential advancement over existing CAR-T therapies by targeting both leukemic blasts and stem cells while sparing healthy cells. The RMAT designation signals regulatory interest, but clinical trial results will be the ultimate arbiter of its success.

What we're watching

Clinical Trial
The success of the Phase 1 clinical trial for SENTI-202 will be critical in validating Senti Bio’s Logic-Gated approach and its potential to address unmet needs in AML and MDS.
Competitive Landscape
How Senti Bio’s Gene Circuit platform differentiates itself from other cell therapy approaches, particularly those utilizing CAR-T technology, will determine its long-term market share and pricing power.
Manufacturing Scale
The ability to scale off-the-shelf NK cell manufacturing for SENTI-202 and other potential therapies will be a key determinant of Senti Bio’s commercial viability and ability to meet patient demand.

Senti Biosciences Advances Logic-Gated CAR-NK Therapy into Pivotal Trial Enrollment

Event summary

  • Senti Biosciences completed enrollment for the Phase 1 clinical trial of SENTI-202, a Logic Gated CAR-NK cell therapy, targeting relapsed or refractory acute myeloid leukemia (R/R AML).
  • Positive clinical data from the trial, presented at ASH 2025, showed deep, MRD-negative, durable complete remissions and a favorable safety profile.
  • The company plans to initiate a pivotal study for SENTI-202 in R/R AML and is exploring expansion into newly diagnosed AML and pediatric AML.
  • SENTI-202 has received both Orphan Drug Designation (ODD) and Regenerative Medicine Advanced Therapy (RMAT) designation.

The big picture

Senti Biosciences’ progress with SENTI-202 represents a significant advancement in the field of cell and gene therapies for AML, a disease with a high unmet need. The Logic Gated CAR-NK approach aims to overcome limitations of existing therapies by targeting both leukemic blasts and stem cells while minimizing off-target toxicity. The RMAT designation offers a potential advantage in navigating the regulatory pathway, but the success of the pivotal trial will be paramount for long-term commercial prospects.

What we're watching

Regulatory Pathway
The FDA discussions in the first half of 2026 will be critical in determining the speed and scope of SENTI-202’s development, particularly given the RMAT designation’s potential for expedited review.
Clinical Efficacy
The durability of the observed complete remissions in the Phase 1 trial will need to be replicated in a larger, pivotal study to support regulatory approval and commercial viability.
Competitive Landscape
The success of Senti’s Logic Gated CAR-NK approach will be weighed against other emerging AML therapies, including next-generation CAR-T and other cell-based treatments, potentially impacting market share and pricing.

Senti Biosciences to Present Gene Circuit Platform at Taipei Healthcare Conference

Event summary

  • Senti Biosciences CEO Timothy Lu will present at the Healthcare Conference Taipei 2026 on February 10, 2026.
  • The presentation, co-hosted by J.P. Morgan, UC Berkeley, and the Regent Taipei, will focus on Senti’s Gene Circuit technology.
  • The eight-minute presentation is scheduled for 10:30 AM local time in Track 1.
  • Senti will use the opportunity to seek investment, R&D, manufacturing, and clinical collaboration partners.

The big picture

Senti Biosciences' participation in this conference highlights the ongoing race to refine cell and gene therapies, a sector attracting significant investment and facing increasing regulatory scrutiny. The company's focus on precision and safety through its Gene Circuit platform positions it within a competitive landscape, and securing strategic partnerships is vital for accelerating development and expanding its market reach. The conference provides a valuable platform to showcase this technology to potential investors and collaborators.

What we're watching

Partnership Potential
The conference provides a direct opportunity for Senti to secure collaborations; the success of these discussions will be a near-term indicator of investor confidence in the Gene Circuit platform's commercial viability.
Technology Validation
The presentation's content and reception will reveal how effectively Senti communicates the technical advantages of its Gene Circuit platform to a sophisticated audience of investors and industry experts.
Pipeline Progression
The pace at which Senti can translate preclinical Gene Circuit demonstrations into clinical trial readouts will be crucial for maintaining investor interest and justifying the company's valuation.

Senti Biosciences Gains Regulatory Momentum with AML Cell Therapy Data

Event summary

  • Senti Biosciences participated in a Virtual Investor CEO Connect segment discussing data related to its AML therapy, SENTI-202.
  • The FDA granted SENTI-202 Regenerative Medicine Advanced Therapy (RMAT) designation, following an earlier Orphan Drug Designation in June.
  • New data from a multinational clinical trial involving 20 patients (18 evaluable) was presented at the American Society of Hematology (ASH) Annual Meeting.
  • SENTI-202 is a Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy targeting relapsed/refractory hematologic malignancies.

The big picture

Senti Biosciences’ progress with SENTI-202 highlights the growing interest in off-the-shelf cell therapies for hematological malignancies. The RMAT designation provides a significant boost, but the company faces the inherent risks of clinical development and the competitive pressures within the rapidly expanding cell and gene therapy market, which is attracting significant investment and innovation.

What we're watching

Regulatory Headwinds
While the RMAT designation accelerates development, the FDA’s evolving standards for cell and gene therapies could still present hurdles for SENTI-202’s approval pathway.
Clinical Efficacy
The initial data from 20 patients is encouraging, but the therapy’s long-term efficacy and safety profile in a larger patient population will be critical to assess.
Market Competition
The CAR-NK cell therapy space is becoming increasingly crowded, and Senti Biosciences will need to demonstrate a clear competitive advantage over existing and emerging therapies.

Senti Bio to Present at J.P. Morgan Showcase Amid Cell Therapy Scrutiny

Event summary

  • Senti Biosciences CEO Timothy Lu will participate in a panel at Biotech Showcase 2026, held January 12–14 in San Francisco.
  • The panel, titled 'Engineering the Future: Advances in Cell and Gene Therapies,' is scheduled for January 13 at 8:00 AM PST.
  • Biotech Showcase is an investor-focused conference attracting global biopharmaceutical executives and investors.
  • The conference serves as a bellwether for the biotechnology and life sciences industry, setting the tone for the coming year.

The big picture

The Biotech Showcase appearance underscores Senti’s ongoing efforts to engage with investors and highlight its Gene Circuit platform. This comes at a time of increased scrutiny for cell and gene therapy companies, with investors demanding clearer paths to commercialization and improved clinical outcomes. The conference provides a valuable opportunity for Senti to address these concerns and demonstrate the potential of its technology, but also exposes it to direct comparison with peers.

What we're watching

Investor Sentiment
The panel appearance will be a key indicator of investor confidence in Senti’s Gene Circuit platform, particularly given recent market volatility impacting cell therapy valuations.
Competitive Landscape
How Senti differentiates its Gene Circuit technology from competitors like Epicrispr and IN8bio, as highlighted by the panel's composition, will influence its ability to secure partnerships and funding.
Clinical Progress
The pace at which Senti can translate preclinical Gene Circuit demonstrations into clinical trial data will be critical for maintaining investor interest and justifying its current valuation.
CID: 494